Karnataka Udyog Mitra under the High Level Clearance Committee (HLCC) of the state government has approved the project of Ozone Group Infrastructure Developers to set up the Pharma Cluster titled ‘Jeevitham’. The Cluster will focus and encourage the manufacture of drug formulations besides biotechnology R&D.
The Pharma Cluster spans over 330 acres and is located at Chikkaballapur which is 30 kilometers away from Bengaluru. Of the 330 acres, 278 acres has been cleared by the State Level Single Window Clearance Committee (SLSWCC) in 2011. The remaining 62 acres was approved here recently. Ten acres of the land is earmarked for biotech R&D.
“We have received the clearance under HLCC which are for investments valued above Rs.50 crore chaired by the Karnataka Chief Minister DV Sadananda Gowda. The concept of a state-of-the-art Pharma Cluster was presented to the state government and the Karnataka pharma industry officials, P Lalith Kumar, vice president, Corporate Strategy, Ozone Group told Pharmabiz.
“This will see Ozone make an investment of over Rs.500 crore in the project. In addition, around 20 to 25 pharma companies would pump in Rs.1400 crore to invest in the facility over the next two years. We plan to commence construction in August this year and the entire phase I of Jeevitham on 278 acres would be operational in August 2014. Further, we are also planning to develop a plug and play R&D hub as part of the initiative which would also be made available for operations,” he added.
Ozone Group has generated promising enquires which it hopes will be converted into positive outcomes. It has appointed KPMG as the Project Associates and Consultants, Jurong as its master planners and engineering consultants, Ernst & Young as the tax consultants and Davis Langdon & Seah as the cost consultants.
Karnataka was strong in the area of development of formulations and there is already a strong presence of biotechnology research and development. There are leading companies including AstraZeneca, Bal Pharma, Micro Labs among other engaged in formulation development. There is also huge scope for contract research and manufacturing services for formulations from Kemwell to Semler Research, Medreich among others in the space.
Ozone will support the Jeevitham initiative as an enabler to set up the logistics and warehouses, training-cum- business centre, serviced apartments, business hotel, truck terminal, residential development besides ancillary services like printing, packaging to facilitate operational efficiencies.
Pharmabiz had earlier reported that the Jeevitham Pharma Cluster will have serviced plots measuring from 1, 5 to 10 and 20 acres to suit the varying needs of pharma formulation production and technology development.
Moreover the global pharma market is expected to provide contract manufacture opportunity for generics as drugs worth $13 billion have gone off patent in US in 2007 and another $60 billion will go off patent in 2012.
The Pharma Cluster spans over 330 acres and is located at Chikkaballapur which is 30 kilometers away from Bengaluru. Of the 330 acres, 278 acres has been cleared by the State Level Single Window Clearance Committee (SLSWCC) in 2011. The remaining 62 acres was approved here recently. Ten acres of the land is earmarked for biotech R&D.
“We have received the clearance under HLCC which are for investments valued above Rs.50 crore chaired by the Karnataka Chief Minister DV Sadananda Gowda. The concept of a state-of-the-art Pharma Cluster was presented to the state government and the Karnataka pharma industry officials, P Lalith Kumar, vice president, Corporate Strategy, Ozone Group told Pharmabiz.
“This will see Ozone make an investment of over Rs.500 crore in the project. In addition, around 20 to 25 pharma companies would pump in Rs.1400 crore to invest in the facility over the next two years. We plan to commence construction in August this year and the entire phase I of Jeevitham on 278 acres would be operational in August 2014. Further, we are also planning to develop a plug and play R&D hub as part of the initiative which would also be made available for operations,” he added.
Ozone Group has generated promising enquires which it hopes will be converted into positive outcomes. It has appointed KPMG as the Project Associates and Consultants, Jurong as its master planners and engineering consultants, Ernst & Young as the tax consultants and Davis Langdon & Seah as the cost consultants.
Karnataka was strong in the area of development of formulations and there is already a strong presence of biotechnology research and development. There are leading companies including AstraZeneca, Bal Pharma, Micro Labs among other engaged in formulation development. There is also huge scope for contract research and manufacturing services for formulations from Kemwell to Semler Research, Medreich among others in the space.
Ozone will support the Jeevitham initiative as an enabler to set up the logistics and warehouses, training-cum- business centre, serviced apartments, business hotel, truck terminal, residential development besides ancillary services like printing, packaging to facilitate operational efficiencies.
Pharmabiz had earlier reported that the Jeevitham Pharma Cluster will have serviced plots measuring from 1, 5 to 10 and 20 acres to suit the varying needs of pharma formulation production and technology development.
Moreover the global pharma market is expected to provide contract manufacture opportunity for generics as drugs worth $13 billion have gone off patent in US in 2007 and another $60 billion will go off patent in 2012.
No comments:
Post a Comment